glp-1 agonist and heart failure Mechanisms of Receptor Agonists in HFpEF: Exploring Weight-Dependent Independent Drivers of Therapeutic Benefit GLP-1 Agonists in Cardiovascular Diseases:
Description
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
Behind the scenes, researchers are studying several new injectable medications that work in similar ways
And am I a candidate for medication like this
Its worth noting that GLP-1RAs do not result in cytochrome-dependent or transporter-mediated drug-drug interactions
Kamrul-Hasan, A.B.M
JAMA 2014;311:1641-51
